FDA Proposes Revised Payor Communications Draft Guidance to Formally Include Devices and Reflect New Statutory Safe Harbor While Balancing Substantial Government Interests
The U.S. Food and Drug Administration’s 2026 Draft Payor Guidance would update the framework for communications between drug and device manufacturers and payors, including guidance on healthcare…
Read the full articleYou might also wanna read
FDA Draft Guidance Allows Gene Therapy Companies to Leverage Existing Data for Faster Product Approvals
On June 2, the US Food and Drug Administration (FDA) released a new draft guidance called “Leveraging Prior Knowledge in the Development of
jdsupra.com·28d ago
FDA PCAC Hearing July 2026: What's at Stake for Compounded Peptide Access
Follow the July 23-24, 2026 FDA hearing on peptide compounding, get hearing updates, and tell the FDA your position before the comment deadl
pepmed.org·9d ago
FTC Proposes Order to Resolve Anticompetitive Practices and Protect Healthcare Consumers
Author: Amy Asubonteng June 26, 2026 HRRC supports both the press release and the call to action given by the Federal Trade Commission. As h
US FDA proposes new rule to simplify drug manufacturing registration
The agency said the rule would improve supply chain transparency, enhance product traceability, reduce registration costs and increase regul
FDA releases draft guidance to accelerate gene therapy development
The agency seeks to help streamline development while maintaining rigorous safety standards.
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
Stronger safeguards are needed to ensure independent and transparent recommendations Glucagon-like peptide-1 (GLP-1) receptor agonists and r
bmj.com·21d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.